Aliment Pharmacol Ther 1996; 10: 1037–1048.

Index

24-h acidity, 523
5-amino salicyclic acid (5-ASA), 941, 949
5HT-receptor antagonists, 597
6-mercaptopurine, 1
99mTc-HMPAD, 123
Aabakken, L., Osnes, M. & Frenzel, W., Gastrointestinal tolerability of lornoxicam compared to that of naproxen in healthy male volunteers, 151
abdominal pain, upper, 83
Acciuffi, S., Ghosh, S. & Ferguson, A., Strengths and limitations of the Crohn's disease activity index, revealed by an objective gut lavage test of gastrointestinal protein loss, 321
acetyl-5-ASA, 941
acetylcholine, 875
acid inhibition, 559
acid secretion, 905
acid, 573
acidity, 187
acid-suppressing drugs, 889
acute pancreatitis, 23
adverse events, 23, 151, 949
Aggestrup, S. *see* Hendel, J.
agonists, 859
Ajie, H. *see* Kasho, V.N.
allopurinol, 737
aminosalicylates, 1
ammonia, 681
amoxycillin suspension, 633
amoxycillin, 165,193, 263, 285, 295, 303, 619, 997, 1001, 1029
Annibale, B., Rindi, G., D'Ambra, G., Marignani, M., Solcia, E., Bordi, C. & Delle Fave G., Antral gastrin cell hyperfunction and *Helicobacter pylori* infection, 607
anorexia, 579
antacids, 889
Anthony, A., Review article: β -adrenoreceptor agonists—future anti-inflammatory drugs for the gastrointestinal tract?, 859
antibiotic delivery, 633
antibiotics, 23, 835
anticonvulsants, 23
anti-Helicobacter pylori antibiotics, 1021
anti-Helicobacter pylori therapy, 1021
anti-inflammatory agents, 23
antimicrobial therapy, 119, 619, 1001
antineoplastic agents, 23
antisecretory drugs, 187
antiviral agents, 23
Anton, P.A. *see* Bernstein, C.N.
Antonacci, M.-A. *see* Ardizzone, S.
antral G cell hyperfunction, 609
Ardizzone, S., Petrillo, M., Antonacci, M.-A. & Bianchi Porro, G., Sucralfate and hydrocortisone enemas in the treatment of active ulcerative proctitis—a randomized single blind comparative study, 957
Arlander, E., Öst, Å., Ståhlberg, D. & Löfberg, R., Ropivacaine gel in active distal ulcerative colitis and protitis—a pharmacokinetic and exploratory clinical study, 73
Armstrong, D. *see* Dorta, G.
arterial oxygen saturation, 981
Artinian, L. *see* Bernstein, C.N.
Asaka, M. *see* Kato, M.
ascites, 801
asymptomatic carrier, 199
Atherton, J.C., Cullen, D.J.E., Kirk, G.E., Hawkey, C.J. & Spiller, R.C., Enhanced eradication of *Helicobacter pylori* by pre- versus post-prandial amoxycillin suspension with omeprazole: implications for antibiotic therapy, 631
autonomic neuropathy, 403
Axon, A.T.R. *see* Bate, C.M.
Axon, A.T.R. *see* Bell, G.D.
azathiropurine, 1
Azcona, C., Castro, L., Crespo, E., Jiménez, M. & Sierrasesúmaga, L., Megestrol acetate therapy for anorexia and weight loss in children with malignant solid tumours, 577
azithromycin, 997

bacteria, 157
bacterial overgrowth, 559
β-adrenoreceptors, 859
Bak, Y.-T. *see* Evans, P.R.
Baker, J.P. *see* Steinhart, A.H.
Bakker, W. *see* Gan, K.-H.
Ballinger, A. *see* Mulcahy, H.E.
Balm, R.K. *see* Camilleri, M.
Bardhan, K.D. *see* Raju, G.S.
Bardhan, K.D. *see* Wyeth, J.W.
Bargiggia, S. *see* Lazzaroni, M.
Bargiggia, S. *see* Parente, F.
Baron, J.H. *see* Harris, A.W.
barostat, 919
Barthelemy, P. *see* Delchier, J.C.
basal acid output, 497
Bate, C.M. *see* Bell, G.D.
Bate, C.M., Griffin, S.M., Keeling, P.W.N., Axon, A.T.R., Dronfield, M.W., Chapman, R.W.G., O'Donoghue, D., Calam, J., Crowe, J., Mountford, R.A., Watts, D.A., Taylor, M.D. & Richardson, P.D.I., Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis, 547
Becker, T. *see* Labenz, J.
Belin, T.R. *see* Bernstein, C.N.
Bell, G.D., Bate, C.M., Axon, A.T.R., Tildesley, G., Martin, J.L., Taylor, M.D. & Richardson, P.D.I., Symptomatic and

© 1996 Blackwell Science Ltd

endoscopic duodenal ulcer relapse rates 12 months following *Helicobacter pylori* eradication treatment with omeprazole and amoxycillin with or without metronidazole, 637
Bell, G.D., Conference report: duodenal ulcer trial reports at the European *Helicobacter pylori* Study Group, Edinburgh 1995, 49
Bell, N.J.V. & Hunt, R.H., Time to maximum effect of lansoprazole on gastric pH in normal male volunteers, 897
Bengoufa, D. *see* Canva-Delcambre, V.
Bensi, G. *see* Lazzaroni, M.
Benson, M.J. *see* Collins, C.E.
Beresford, J. *see* Raju, G.S.
Bernstein, C.N., Seeger, L.L., Anton, P.A., Artinian, L., Geffrey, S., Goodman, W., Belin, T.R. & Shanahan, F., A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with inflammatory bowel disease: a pilot-study, 777
beta-interferon, 807
Bethke, T.D. *see* Van Rensburg, C.J.
Bianchi Porro, G. *see* Ardizzone, S.
Bianchi Porro, G. *see* Lazzaroni, M.
Bianchi Porro, G. *see* Parente, F.
bile acid therapy, 653, 699
bile acid, 927
biliary dyskinesia, 421
biliary secretion, 967
bioavailability, 295
bismuth, 459
Bliesath, H. *see* Hartmann, M.
blood pressure, 981
Blum, A.L. *see* Dorta, G.
Bodger, K., Daly, M.J. & Heatley, R.V., Prescribing patterns for dyspepsia in primary care: a prospective study of selected general practitioners, 889
Bodger, K., Daly, M.J., Heatley, R.V. & Williams, D.R.R., Clinical economics review: gastroenterology, 55
Boer, R.O. *see* Van Bodegraven, A.A.
Boland, C.R. *see* Yoshimura, K.
bone mass, 777
Bordi, C. *see* Annibale, B.
Börsch, G. *see* Labenz, J.
Botha, J.F. *see* Van Rensburg, C.J.
Bouhassira, D. *see* Coffin, B.
Bovani, I. *see* Neri, M.
bowel habit, 559
Bozzola, L. *see* Pilotto, A.
Braden, B. *see* Pommerien, W.
Branca, G. *see* Tursi, A.
Braun, M. *see* Pommerien, W.
Brignola, C. *see* Gionchetti, P.
Brill, S. *see* Moshkowitz, M.
Broadbent, A. *see* Weldon, M.J.
Brunner, H. & The Austro-Cis Study Group, Factors affecting dose selection and outcome of cisapride treatment for dyspepsia in primary care, 587
Brzezinski, A. *see* Steinhart, A.H.
Buckley, M.J.M. *see* Wyeth, J.W.
budesonide, 487
Bujanover, Y. *see* Moshkowitz, M.
Burnham, W.R. *see* Collins, C.E.
butyrate, 729

cachexia, 579
Calam, J. *see* Bate, C.M.
calcium supplementation, 777
Camilleri, M., Balm, R.K. & Zinsmeister, A.R., Symptomatic improvement with one-year cisapride treatment in neuropathic chronic intestinal dysmotility, 403
Cammarota, G. *see* Tursi, A.
Cammarota, G., Tursi, A., Papa, A., Montalto, M., Veneto, G., Cuoco, L., Fedeli, G. & Gasbarrini, G., *Helicobacter pylori* eradication using one-week low-dose lansoprazole plus amoxycillin and either clarithromycin or azithromycin, 997
Campbell, B.J. *see* Stretch, G.L.
Campbell, C.J. *see* McColm, A.A.
Campieri, M. *see* Gionchetti, P.
Canali, A. *see* Lazzaroni, M.
cancer, 579
Canva-Delcambre, V., Jacquot, S., Robinet, E., Lémann, M., Drouet, C., Labalette, M., Dessaint, J.-P., Bengoufa, D., Rabian, C., Modigliani, R., Wijdenes, J., Revillard, J.-P. & Colombel, J.-F., Treatment of severe Crohn's disease with anti-CD4 monoclonal antibody, 721
Cariem, A.K. *see* Van Rensburg, C.J.
Carli, G. *see* Dalla Libera, M.
Caspary, W.F. *see* Wehrmann, T.
Castro, L. *see* Azcona, C.
CCK-receptor antagonists, 411
Celle, G. *see* Savarino, V.
cetraxate, 97
Chambers, S. *see* Weldon, M.J.
Chamiot-Prieur, C. *see* Lémann, M.
Chapman, R.W.G. *see* Bate, C.M.
Chaumeil, J.-C. *see* Landry, C.
Chaussade, S. *see* Delchier, J.C.
Chaussade, S. *see* Landry, C.
Cheng, S. *see* Kasho, V.N.
children, 579
cholecystectomy, 653
Chollet, R. *see* Coffin, B.
chronic hepatic encephalopathy, 681
chronic hepatitis B, 807
chronic hepatitis, 961
chronic pancreatitis, 427
Chu, C.-M. *see* Lin, D.-Y.
Ciociola, A.A. *see* Peterson, W.L.
Ciociola, A.A., Webb, D.D., Heath, A. & Walsh, J.H., Effects of ranitidine bismuth citrate on gastric acid secretion and gastrin release in subjects with and without *Helicobacter pylori* infection, 905
Cipriano, J. *see* Goudie, B.M.
cirrhosis, 219, 681, 961
cisapride, 403, 589, 875
clarithromycin, 119, 251, 263, 275, 279, 285, 619, 997, 1015, 1029
classical triple therapy, 211

© 1996 Blackwell Science Ltd

Clayton, N.M., Oakley, I., Williams, L.V. & Trevethick, M.A., The role of acid in the pathogenesis of indomethacin-induced gastric antral ulcers in the rat, 339
clinical economics, 55
clinical symptoms, 73
clinical trial, 119, 619, 1001
Clostridium difficile, 157, 835
Clouse, R.E. *see* Staiano, A.
cobalamin levels, 543
coeliac disease, 671
Coffin, B., Bouhassira, D., Chollet, R., Fraitag, B., De Meynard, C., Geneve, J., Lemann, M., Willer, J.-C. & Jian, R., Effect of the kappa agonist fedotizine on perception of gastric distension in healthy humans, 919
colchicine, 961
Cole, R.A. *see* Malaty, H.
Cole, R.A. *see* Yousfi, M.M.
Collins, C.E., Benson, M.J., Burnham, W.R. & Rampton, D.S., Picotamide inhibition of excess *in vitro* thromboxane B_2 release by colorectal mucosa in inflammatory bowel disease, 315
Colombel, J.-F. *see* Canva-Delcambre, V.
Colombel, J.-F. *see* Lémann, M.
Colombo, E. *see* Parente, F.
colonic lavage solutions, 815
colonic mucosa, 737
colonoscopy, 815, 981
complications, 671
Connolly, P.C. *see* McColm, A.A.
continuous gastric nutrition, 967
Cooper, B.T. *see* Gough, A.L.
core, 199
corticosteroids, 1
cost effectiveness, 55, 865
Cottrell, J. *see* Grimley, C.E.
Cottrell, J. *see* Reilly, T.G.
counter-irritation, 919
Couturier, D. *see* Landry, C.
Crespo, E. *see* Azcona, C.
Crohn's disease, 1, 123, 309, 315, 321, 777, 851
Crowe, J. *see* Bate, C.M.
Cuccurullo, F. *see* Neri, M.
Cullen, D.J.E. *see* Atherton, J.C.
Cuoco, L. *see* Cammarota, G.
Cuoco, L. *see* Tursi, A.
cyanocobalamin absorption, 543
cyclosporine, 1
cysteine, 737
cystic fibrosis, 433
cystine, 737
cytokines, 933
cytoprotection, 927

D cell, 609
D'Amato, M. *see* Scarpignato, C.
D'Ambra, G. *see* Annibale, B.
Da Cas, R. *see* Tebano, M.T.
Dalla Libera, M., Pazzi, P., Carli, G., Gamberini. S., Scagliarini, R., Merighi, A. & Gullini, S., High effectiveness and safety of one-week antibiotic regimen in *Helicobacter pylori* eradication, 203
Daly, M.J. *see* Bodger, K.
Dankert, J. *see* Van der Hulst, R.W.M.
De Boer, W.A. *see* Lai, J.Y.L.
De Fanis, D. *see* Spadaccini, A.
De Koster, E.H. *see* Wyeth, J.W.
De Meynard, C. *see* Coffin, B.
Delbarre, S.G. *see* Yoshimura, K.
Delchier, J.C., Elamine, I., Goldfain, D., Chaussade, S., Barthelemy, P. & Idström, J.P., Omeprazole–amoxycillin versus omeprazole–amoxycillin–clarithromycin in the eradication of *Helicobacter pylori*, 263
Delle Fave, G. *see* Annibale, B.
Denk, H. *see* Stupnicki, Th.
Dessaint, J.-P. *see* Canva-Delcambre, V.
Devaux, C. *see* Marteau, P.
dexloxiglumide, 411
Di Mario, F. *see* Pilotto, A.
Di Virgilio, M. *see* Spadaccini, A.
Diab, F.H. & Marshall, J.B., The palatability of five colonic lavage solutions, 815
diagnosis, 289
Dickey, W., Kenny, B.D. & McConnell, J.B., Effect of proton pump inhibitors on the detection of *Helicobacter pylori* in gastric biopsies, 289
diclofenac, 565
diet therapy, 671
Dijkmans, B.A.C. *see* Ten Wolde, S.
dirithromycin, 269
disease activity, 123
dissolution, 433
Dixon, J.S. & Wood, J.R., Letter to the Editors, 1036
Dixon, J.S. *see* Tillman, L.A.
Dorta, G., Nicolet, M., Vouillamoz, D., Margalith, D., Blum, A.L., Armstrong, D. & Saraga, E., Effects of misoprostol on healing and prevention of biopsy-induced gastroduodenal lesions occurring during the administration of diclofenac to volunteers, 563
dosage, 397
dose timing, 633
Drake, F.M. *see* Tillman, L.A.
Driessen, W.M.M. *see* Lai, J.Y.L.
Dronfield, M.W. *see* Bate, C.M.
Drouet, C. *see* Canva-Delcambre, V.
drug safety, 459
drug therapy, 671
dual therapy, 49, 251
Duggan, A.E. *see* Wyeth, J.W.
duodenal ulcer relapse, 639
duodenal ulcer, 193, 203, 251, 279, 303, 507, 609, 829
Dwarakanath, A.D. *see* Stretch, G.L.
dysmotility, 403
dyspepsia, 83, 147, 589, 889

early evening dosing, 187
ECL cells, 497

© 1996 Blackwell Science Ltd

economic evaluation, 55, 699
economics, 707
effervescent and standard formulations, 913
efficacy, 321, 397
Elamine, I. *see* Delchier, J.C.
elderly, 1021
electron microscopy, 181
Eloff, F.P. *see* Van Rensburg, C.J.
Elton, E. & Hanauer, S.B., Review article: the medical management of Crohn's disease, 1
El-Zimaity, H.M.T. *see* Malaty, H.
El-Zimaity, H.M.T. *see* Yousfi, M.M.
endoscopic manometry, 421
endoscopy, 289
enema distribution, 327
enteric coatings, 433, 771
enteritis, 671
eradication failures, 165
eradication therapy, 139, 469, 829
eradication, 207, 263, 303, 367, 625, 639, 843, 1005, 1009
erosive oesophagitis, 373
erythromycin, 421, 967
Escherichia coli, 157
Estrada, R. *see* Laine, L.
Evans, P.R., Bak, Y.-T. & Kellow, J.E., Mebeverine alters small bowel motility in irritable bowel syndrome, 787
evening dosing, 523
extra-corporeal lithotripsy, 699
extra-corporeal shock wave lithotripsy, 653

Fairclough, P.D. *see* Mulcahy, H.E.
Faller, L.D. *see* Kasho, V.N.
famotidine, 111, 743, 749
Farthing, M.J.G. *see* Mulcahy, H.E.
fatty acid, 667
Fedeli, G. *see* Cammarota, G.
Fedeli, G. *see* Tursi, A.
Feldman, M. *see* Lee, M.
Ferguson, A. *see* Acciuffi, S.
Ferretti, M. *see* Gionchetti, P.
Festen, H.P.M. *see* Schenk, B.E.
FK506, 933
follow-up, 647
Forrest, E.H., Jalan, R. & Hayes, P.C., Review article: renal circulatory changes in cirrhosis—pathogenesis and therapeutic prospects, 219
Forrest, E.H., Jalan, R., Redhead, D.N. & Hayes, P.C., Differing actions of the acute administration of propranolol and isosorbide-5-mononitrate on the portal circulation, 795
Forrest, E.H., Stanley, A.J., Redhead, D.N., McGilchrist, A.J. & Hayes, P.C., Clinical response after transjugular intrahepatic portosystemic stent shunt insertion for refractory ascites in cirrhosis, 801
Foster, C.S. *see* Gough, A.L.
Fraitag, B. *see* Coffin, B.
Franceschi, M. *see* Pilotto, A.
Francis, M.R. *see* McColm, A.A.
Franco, S. *see* Lewis, S.J.
Fraser, A.G., Sawyerr, A.M., Hudson, M., Smith, M.S.H. & Pounder, R.E., Morning versus evening dosing of lansoprazole 30 mg daily on twenty-four-hour intragastric acidity in healthy subjects, 523
free radicals, 737
Frenzel, W. *see* Aabakken, L.
Fukanaga, K. *see* Laine, L.
functional bowel disorders, 597

G cell, 609
Gabe, S.M. *see* Harris, A.W.
gall-bladder motility, 421
gall-bladder stones, 653, 699
Gamberini, S. *see* Dalla Libera, M.
Gan, K.-H., Geus, W.P., Bakker, W., Lamers, C.B.H.W. & Heijerman, H.G.M., *In vitro* dissolution profiles of enteric coated microsphere/microtablet pancreatin preparations at different pH values, 771
Garcia, F. *see* Laine, L.
Garrett, A.D. *see* Gough, A.L.
Gasbarrini, G. *see* Cammarota, G.
Gasbarrini, G. *see* Tursi, A.
gastric acid determination, 353
gastric acid secretion, 61, 339, 507, 743
gastric acidity, 897
gastric adaptation, 133
gastric antral ulceration, 339
gastric compliance, 919
gastric ECL cells, 507
gastric emptying, 411, 427, 715, 967
gastric injury, 133
gastric juice, 105
gastric lesions, 97, 933
gastric mucin, 111
gastric mucosal damage, 333
gastric pH, 367, 913
gastric secretion, 411
gastric sensitivity, 919
gastric tone, 919
gastric ulcer, 203, 381, 573, 927
gastrin, 609, 905
gastrinoma, 61
gastritis, 289, 985, 1021
gastroduodenal lesions, 565
gastrointestinal endoscopy, 815
gastrointestinal hormones, 715
gastrointestinal surgery, 707
gastrointestinal transit, 715
gastro-oesophageal reflux disease, 373, 441, 543, 865
gastro-oesophageal, 549
Geffrey, S. *see* Bernstein, C.N.
Gendre, J.-P. *see* Lémann, M.
general practice, 147, 233
Geneve, J. *see* Coffin, B.
Gent, A.E. *see* Hartley, M.G.
Genta, R.M. *see* Malaty, H.
Genta, R.M. *see* Yousfi, M.M.
Geus, W.P. *see* Gan, K.-H.

© 1996 Blackwell Science Ltd

Geuskens, L.M. *see* Lai, J.Y.L.
Ghosh, S. *see* Acciuffi, S.
Gibril, F. *see* Termanini, B.
Gilat, T. *see* Moshkowitz, M.
Gilvarry, J. *see* Wyeth, J.W.
Gionchetti, P., Campieri, M., Venturi, A., Rizzello, F., Ferretti, M., Brignola, C. & Miglioli, M., Systemic availability of 5-aminosalicylic acid: comparison of delayed release and an azo-bond preparation, 601
Girdwood, A.H. *see* Van Rensburg, C.J.
Goddard, A. & Spiller, R., Letter to the Editors, 669
Goddard, A.F. & Spiller, R.C., *Helicobacter pylori* eradication in clinical practice: one-week low-dose triple therapy is preferable to classical bismuth based triple therapy, 1009
Goddard, A.F. & Spiller, R.C., The effect of omeprazole on gastric juice viscosity, pH and bacterial counts, 105
Goffin, H. *see* Simon, B.
Goldfain, D. *see* Delchier, J.C.
Goodlad, R.A., Letter to the Editors, 215
Goodman, W. *see* Bernstein, C.N.
Goto, H. *see* Hisanaga, Y.
Goto, H. *see* Tachi, K.
Goudie, B.M., McKenzie, P.E., Cipriano, J., Griffin, E.M. & Murray, F.E., Repeat prescribing of ulcer healing drugs in general practice-prevalence and underlying diagnosis, 147
Gough, A.L., Long, R.G., Cooper, B.T., Foster, C.S., Garrett, A.D. & Langworthy, C.H., Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis, 529
Gould, S.R. *see* Weldon, M.J.
GR122311X, 625
Grace, R.H. *see* Hartley, M.G.
Graf, K. *see* Stupnicki, Th.
Graham, D.Y. *see* Malaty, H.
Graham, D.Y. *see* Woods, K.L.
Graham, D.Y. *see* Yousfi, M.M.
Great Britain, 83
Greaves, R.R.S.H. *see* Mulcahy, H.E.
Green, A.T. *see* Jenkins, A.P.
Griffin, E.M. *see* Goudie, B.M.
Griffin, M.G. & Miner, P.B., Review article: refractory distal colitis—explanations and options, 39
Griffin, S.M. *see* Bate, C.M.
Grimley, C.E., West, J.M., Loft, D.E., Cottrell, J., Mann, S.G., Stauffer, L. & Nwokolo, C.U., Early and late effects of low-dose famotidine, ranitidine or placebo on pentagastrin-stimulated gastric acid secretion in man, 743
Grinham, C.J. *see* McColm, A.A.
Grundling, H. de K. *see* Van Rensburg, C.J.
Guan, R. *see* How, W.
Guan, R., Yeoh, K.G., Yap, I., Kang, J.Y., Wee, A. & Smith, R., Subcutaneously-administered recombinant human β-interferon in the treatment of chronic hepatitis B virus infection, 807
Guillou, P.J., Windsor, A.J. & Nejim, A., Clinical economics review: the health-care economic implications of minimal access gastrointestinal surgery, 707
Gullini, S. *see* Dalla Libera, M.
Gummett, P.A. *see* Wyeth, J.W.
Guslandi, M., Letter to the Editor, 669
gut, 859

H^+,K^+-ATPase inhibitors, 61
H_2-receptor antagonist, 111, 147, 339, 387, 865
haemoglobin concentration, 333
Hallak, A. *see* Moshkowitz, M.
Halphen, M. *see* Lémann, M.
Hanauer, S.B. *see* Elton, E.
Harris, A. & Misiewicz, J.J., Letter to the Editor, 1035
Harris, A.W., Pryce, D.I., Gabe, S.M., Karim, Q.N., Walker, M.M., Langworthy, H., Baron, J.H. & Misiewicz, J.J., Lansoprazole, clarithromycin and metronidazole for seven days in *Helicobacter pylori* infection, 1005
Hartley, M.G., Hudson, M.J., Swarbrick, E.T., Grace, R.H., Gent, A.E. & Hellier, M.D., Sulphasalazine treatment and the colorectal mucosa-associated flora in ulcerative colitis, 157
Hartmann, M., Theiß, U., Huber, R., Lühmann, R., Bliesath, H., Wurst, W. & Lücker, P.W., Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole, 359
Hawkey, C.J. *see* Atherton, J.C.
Hayakawa, T. *see* Hisanaga, Y.
Hayakawa, T. *see* Tachi, K.
Hayes, P.C. *see* Forrest, E.H.
HBV, 199
health economics, 233
heartburn, 83, 549
Heath, A. *see* Ciociola, A.A.
Heatley, R.V. *see* Bodger, K.
Heijerman, H.G.M. *see* Gan, K.-H.
Helicobacter pylori treatment, 279
Helicobacter pylori, 49, 119, 139, 165, 181, 193, 203, 207, 211, 241, 251, 263, 269, 275, 285, 289, 295, 303, 367, 469, 497, 609, 619, 625, 633, 639, 647, 821, 829, 843, 889, 905, 997, 1001, 1005, 1009, 1015, 1029
Hellier, M.D. *see* Hartley, M.G.
Hendel, J., Hendel, L. & Aggestrup, S., Letter to the Editors, 447
Hendel, L. *see* Hendel, J.
hepatitis B, 667
hepato-renal failure, 801
Hermans, J. *see* Ten Wolde, S.
Heyman, D.J. *see* Houghton, L.A.
Hifumi, K. *see* Yuno, K.
Hirose, M. *see* Watanabe, S.
Hirschowitz, B.I., Mohnen, J. & Shaw, S., Long-term treatment with lansoprazole for patients with Zollinger–Ellison syndrome, 507
Hirschowitz, B.I., Mohnen, J. & Shaw, S., Long-term treatment with lansoprazole of patients with duodenal ulcer and basal acid output of more than 15 mmol/h, 497
Hiruki, T. *see* Steinhart, A.H.
Hisanaga, Y., Goto, H., Tachi, K., Hayakawa, T. & Sugiyama, S., Implication of nitric oxide synthase activity in the genesis of water immersion stress-induced gastric lesions in rats: the protective effects of FK506, 933
Hokari, K. *see* Kato, M.

© 1996 Blackwell Science Ltd

Honiball, P.J. *see* Van Rensburg, C.J.
Horváth, Cs. *see* Hunyady, B.
Houghton, L.A., Heyman, D.J. & Whorwell, P.J., Symptomatology, quality of life and economic features of irritable bowel syndrome—the effect of hypnotherapy, 91
How, W., Ng, W.C., Tan, M.F., Seet, B.L. & Guan, R., Viral nucleotide changes in asymptomatic hepatitis B carriers undergoing interferon treatment, 199
Howdle, P.D. *see* O'Mahony, S.
HPLC, 737
Huang, J. *see* Sridhar, S.
Huber, R. *see* Hartmann, M.
Hudson, M. *see* Fraser, A.G.
Hudson, M.J. *see* Hartley, M.G.
humans, 919
Hunt, R. *see* Sridhar, S.
Hunt, R.H. *see* Bell, N.J.V.
Hunter, J.O. *see* Kelly, S.M.
Hunter, J.O. *see* Reynolds, P.D.
Hunyady, B., Juricskay, I., Pakodi, F., Horváth, Cs. & Mózsik, Gy., Diagnostic interpretation of 24-hour intragastric pH-metry using a pattern recognition method, 353
Hussaini, S.H., Clinical economics review: the management of gallstone disease, 699
hydrocortisone enema, 957
hydrogen ion output, 743
hypertension, 795
hypnotherapy, 91

Idström, J.P. *see* Delchier, J.C.
Idström, J.-P. *see* Pommerien, W.
Iishi, H. *see* Yuno, K.
immunosuppressants, 1, 23
in vitro dissolution characteristics, 771
indomethacin, 339, 573
infection, 835
infiltration, 181
inflammation, 859
inflammatory bowel disease, 1, 39, 123, 157, 315, 321, 661, 777
interferon, 199
intestinal microflora, 157
intestinal perfusion, 321
intestinal pseudo-obstruction, 403
intragastric pH-metry, 187, 353
irritable bowel syndrome, 91, 597, 787
isosorbide-5-mononitrate, 795
Iwazaki, R. *see* Watanabe, S.

Jacquot, S. *see* Canva-Delcambre, V.
Jalan, R. *see* Forrest, E.H.
Jalan, R., Seery, J.P. & Taylor-Robinson, S.D., Review article: pathogenesis and treatment of chronic hepatic encephalopathy, 681
Jansen, J.B.M.J. *see* Laheij, R.J.F.
Janssen, M. *see* Ten Wolde, S.
Jaup, B.H. & Norrby, A., Comparison of two low-dose one-week triple therapy regimens with and without metronidazole for cure of *H. pylori* infection, 275
jejunal motility, 787
Jenkins, A.P., Green, A.T. & Thompson, R.P.H. Essential fatty acid supplementation in chronic hepatitis B, 665
Jensen, D.M. *see* Kasho, V.N.
Jensen, R.T. *see* Termanini, B.
Jian, R. *see* Coffin, B.
Jiménez, M. *see* Azcona, C.
Johnston, B.T. *see* Watson, R.G.P.
Jones, R.H., Clinical economics review: gastrointestinal disease in primary care, 233
Joseph, A.E.A. *see* Weldon, M.J.
Juricskay, I. *see* Hunyady, B.

Kagaya, H. *see* Kato, M.
Kallal, S.M. *see* Lee, M.
Kang, J.Y. *see* Guan, R.
Karim, Q.N. *see* Harris, A.W.
Kasho, V.N., Cheng, S., Jensen, D.M., Ajie, H., Lee, W.-N.P. & Faller, L.D., Feasibility of analyzing [^{13}C]urea breath tests for *Helicobacter pylori* by gas chromatography-mass spectrometry in the selected ion monitoring mode, 985
Katagiri, M. *see* Kato, M.
Kato, M., Asaka, M., Kudo, M., Sukegawa, M., Katagiri, M., Koshiyama, T., Kagaya, H., Nishikawa, K., Hokari, K., Takeda, H. & Sugiyama, T., Effects of lansoprazole plus amoxycillin on curing *Helicobacter pylori* infection in Japanese peptic ulcer patients, 821
Keeling, P.W.N. *see* Bate, C.M.
Keighley, M.R.B., Review article: the management of pouchitis, 449
Keller, J.J. *see* Van der Hulst, R.W.M.
Kellow, J.E. *see* Evans, P.R.
Kelly, S.M. & Hunter, J.O., The effect of a non-absorbable fat substitute, sucrose polyester, on gastrointestinal function, 715
Kenny, B.D. *see* Dickey, W.
Kersey, K. *see* Watson, R.G.P.
Kiefe, C. *see* Woods, K.L.
Kirk, G.E. *see* Atherton, J.C.
Kisfalvi, I. *see* Scarpignato, C.
Kitamura, T. *see* Watanabe, S.
Klinkenberg-Knol, E.C. *see* Schenk, B.E.
Klinkert, G. *see* McColm, A.A.
Konikoff, F.M. *see* Moshkowitz, M.
Koshiyama, T. *see* Kato, M.
Kraus, E. *see* Yoshimura, K.
Kudo, M. *see* Kato, M.
Kuipers, E.J. *see* Schenk, B.E.

Labalette, M. *see* Canva-Delcambre, V.
Labenz, J., Stolte, M., Peitz, U., Tillenburg, B., Becker, T. & Börsch, G., One-week triple therapy with omeprazole, amoxycillin and either clarithromycin or metronidazole for cure of *Helicobacter pylori* infection, 207
lactose handling, 765
Laheij, R.J.F., Jansen, J.B.M.J., Van de Lisdonk, E.H., Severens, J.L. & Verbeek, A.L.M., Review article: symptom improvement through eradication of *Helicobacter pylori* in patients

© 1996 Blackwell Science Ltd

with non-ulcer dyspepsia, 843
Lai, J.Y.L., De Boer, W.A., Driessen, W.M.M. & Geuskens, L.M., Long-term follow-up after cure of *Helicobacter pylori* infection with 4 days of quadruple therapy, 645
Laine, L., Estrada, R., Trujillo, M., Fukanaga, K. & Neil, G., Randomized comparison of differing durations of twice-a-day triple therapy for the eradication of *Helicobacter pylori*, 1029
Laine, L., Stein, C., Garcia, F., Trujillo, M., Estrada, R., Prospective evaluation of the macrolide antibiotic dirithromycin for the treatment of *Helicobacter pylori*, 269
Lamers, C.B.H.W. *see* Gan, K.-H.
Lamers, C.B.H.W. *see* Ten Wolde, S.
Landry, C., Vidon, N., Sogni, P., Nepveux, P., Chaumeil, J.-C., Couturier, D. & Chaussade, S., Could oral erythromycin optimize high energy continuous enteral nutrition?, 967
Langdon, D.E., Letter to the Editors, 670
Langworthy, C.H. *see* Gough, A.L.
Langworthy, H. *see* Harris, A.W.
lansoprazole, 61, 275, 381, 523, 529, 757, 821, 897, 997
lansoprazole–antibiotic combinations, 211
laparoscopic cholecystectomy, 699
Larsen, S. *see* Nørregaard, P.
Laterza, F. *see* Neri, M.
Lazzaroni, M., Sangaletti, O., Bargiggia, S., Bensi, G., Canali, A. & Bianchi Porro, G., Twenty-four-hour intragastric acidity following early evening or bedtime administration of roxatidine in duodenal ulcer patients, 187
Le Lu, M. *see* Marteau, P.
Leandro, G. *see* Pilotto, A.
Lee, M., Kallal, S.M. & Feldman, M., Omeprazole prevents indomethacin-induced gastric ulcers in rabbits, 571
Lee, W.-N.P. *see* Kasho, V.N.
Lémann, M. *see* Canva-Delcambre, V.
Lemann, M. *see* Coffin, B.
Lémann, M., Chamiot-Prieur, C., Mesnard, B., Halphen, M., Messing, B., Rambaud, J.-C., Gendre, J.-P., Colombel, J.-F. & Modigliani, R., Methotrexate for the treatment of refractory Crohn's disease, 309
Lembcke, B. *see* Pommerien, W.
Lewis, S.J., Franco, S., Young, G., O'Keefe, S.J.D., Altered bowel function and duodenal bacterial overgrowth in patients treated with omeprazole, 557
Liaw, Y.F. *see* Lin, D.-Y.
Lin, D.-Y., Sheen, I.-S., Chu, C.-M. & Liaw, Y.-F., A prospective randomized trial of colchicine in prevention of liver cirrhosis in chronic hepatitis B patients, 961
lipase, 433
Lipscomb, G.R. & Rees, W.D.W., Gastric mucoasl injury and adaptation to oral and rectal administration of naproxen, 133
Littlewood, J.M. *see* Walters, M.P.
liver function, 219
Löfberg, R. *see* Arlander, E.
Loft, D.E. *see* Grimley, C.E.
Logan, R.P.H. *see* Wyeth, J.W.
Loizzo, A. *see* Tebano, M.T.
Londong, W. *see* Pommerien, W.
Long, R.G. *see* Gough, A.L.
loperamide, 765
lornoxican, 151
Losowsky, M.S. *see* O'Mahony, S.
Lourens, J. *see* Van Bodegraven, A.A.
Louw, C.J. *see* Van Rensburg, C.J.
low-dose, 749
low-dose-H$_2$-antagonist, 743
Lowe, C. *see* Weldon, M.J.
lower oesophageal sphincter, 883
Lücker, R. *see* Hartmann, M.
Lühmann, R. *see* Hartmann, M.
lymphoma, 671
Lysgaard Madsen, J. *see* Nørregaard, P.

Macdonald, C.E. *see* Playford, R.J.
Maconi, G. *see* Parente, F.
macrolide, 269
Magnarini, C. *see* Spadaccini, A.
magnetic resonance spectroscopy, 681
maintenance therapy, 529
maintenance treatment, 381, 603
Malaty, H., El-Zimaity, H.M.T., Genta, R.M., Cole, R.A. & Graham, D.Y., High-dose proton pump inhibitor plus amoxycillin for the treatment or retreatment of *Helicobacter pylori* infection, 1001
malignancy, 387
Mann, S.G. *see* Grimley, C.E.
Mann, S.G. *see* Reilly, T.G.
Mansi, C. *see* Savarino, V.
Margalith, D. *see* Dorta, G.
Marignani, M. *see* Annibale, B.
Marks, I.N. *see* Van Rensburg, C.J.
Marshall, J.B. *see* Diab, F.H.
Marteau, P., Nelet, F., Le Lu, M. & Devaux, C., Adverse events in patients treated with 5-aminosalicylic acid: 1993–1994 pharmacovigilance report for Pentasa in France, 949
Martin, J.L. *see* Bell, G.D.
Masciulli, V. *see* Spadaccini, A.
mass spectrometry, 981
mast cell, 173
maximal acid output, 497
Maxton, D.G., Morris, J. & Whorwell, P.J., Selective 5-hydroxytryptamine antagonism: a role in irritable bowel syndrome and functional dyspepsia, 595
Maxwell, J.D. *see* Weldon, M.J.
McArthur, K.E., Review article: drug-induced pancreatitis, 23
McColm, A.A., McLaren, A., Klinkert, G., Francis, M.R., Connolly, P.C., Grinham, C.J., Campbell, C.J., Selway, S. & Williamson R., Ranitidine bismuth citrate: a novel anti-ulcer agent with different physico-chemical characteristics and improved biological activity to a bismuth citrate–ranitidine admixture, 241
McConnell, J.B. *see* Dickey, W.
McGilchrist, A.J. *see* Forrest, E.H.
McKenzie, P.E. *see* Goudie, B.M.
McLaren, A. *see* McColm, A.A.
McSorley, D.J. *see* Peterson, W.L.
mebeverine, 787

© 1996 Blackwell Science Ltd

Mee, A.S., Rowley, J.L., & The Lansoprazole Clinical Research Group, Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole, 757
Mela, G.S. *see* Savarino, V.
Mele, M.R. *see* Savarino, V.
Merighi, A. *see* Dalla Libera, M.
mesalazine enema, 327
mesalazine, 1, 603, 661, 941
Mesnard, B. *see* Lémann, M.
Messing, B. *see* Lémann, M.
methotrexate, 1, 309, 851
metronidazole, 119, 193, 275, 449
Meuwissen, S.G.M. *see* Schenk, B.E.
meyestrol acetate, 579
midazolam, 981
Miglioli, M. *see* Gionchetti, P.
Miner, P.B. *see* Griffin, M.G.
minimal access, 707
Misiewicz, J.J. *see* Harris, A.
Misiewicz, J.J. *see* Harris, A.W.
misoprostol, 565
Mistry, K.R. *see* Penston, J.G.
Mistry, R. *see* Weldon, M.J.
Miwa, H. *see* Watanabe, S.
Miyazaki, A. *see* Watanabe, S.
Modigliani, R. *see* Canva-Delcambre, V.
Modigliani, R. *see* Lémann, M.
Mohnen, J. *see* Hirschowitz, B.I.
monoclonal anti-CD4 antibody, 721
Montalto, M. *see* Cammarota, G.
Montalto, M. *see* Tursi, A.
morning dosing, 523
Morrill, B.B. *see* Silver, M.T.
Morris, A.I. *see* Stretch, G.L.
Morris, J. *see* Maxton, D.G.
Moshkowitz, M., Konikoff, F.M., Peled, Y., Brill, S., Hallak, A., Tiomny, E., Santo, M., Bujanover, Y. & Gilat, T., One week triple therapy with omeprazole, clarithromycin and tinidazole for *Helicobacter pylori*: differing efficacy in previously treated and untreated patients, 1015
Mountford, R.A. *see* Bate, C.M.
Mózsik, Gy. *see* Hunyady, B.
mucosal blood flow, 97, 133, 933
mucosal injury, 565, 927
mucus viscosity, 105
mucus, 111
Mulcahy, H.E., Greaves, R.R.S.H., Ballinger, A., Patchett, S.E., Riches, A., Fairclough, P.D. & Farthing, M.J.G., A double-blind randomized trial of low-dose versus high-dose topical anaesthesia in unsedated upper gastrointestinal endoscopy, 975
mulicategory analysis, 353
Murdock, R.H., Jr *see* Silver, M.T.
Murray, F.E. *see* Goudie, B.M.

naproxen, 133, 151
national survey, 83
natural history, 387
Neil, G. *see* Laine, L.
Nejim, A. *see* Guillou, P.J.
Nelet, F. *see* Marteau, P.
nephrotoxicity, 603, 941
Nepveux, P. *see* Landry, C.
Neri, M., Susi, D., Bovani, I., Laterza, F., Porreca, E. & Cuccurullo, F., Gastric mucosal infiltration by *Helicobacter pylori* favours bacterial survival after treatment, 181
Neuberger, J. *see* Tang, H.
Ng, W.C. *see* How, W.
Nicolet, M. *see* Dorta, G.
Nishikawa, K. *see* Kato, M.
nitric oxide synthase, 97, 933
nitric oxide, 883
nitroglycerine, 883
nonsteroidal anti-inflammatory drugs, 151, 173, 347
non-ulcer dyspepsia, 263, 441, 647, 843
Norrby, A. *see* Jaup, B.H.
Nørregaard, P., Lysgaard Madsen, J., Larsen, S. & Worning, H., Gastric emptying of pancreatin granules and dietary lipids in pancreatic insufficiency, 427
Nwokolo, C.U. *see* Grimley, C.E.

O'Brien, B.J. *see* Sridhar, S.
O'Donoghue, D. *see* Bate, C.M.
O'Keefe, S.J.D. *see* Lewis, S.J.
O'Mahony, S., Howdle, P.D. & Losowsky, M.S., Review article: the management of the patient with non-responsive coeliac disease, 671
O'Morain, C.A. *see* Wyeth, J.W.
Oakley, I. *see* Clayton, N.M.
oesophageal motility, 875
oesophageal motor activity, 883
oesophagitis, 507
Oide, H. *see* Watanabe, S.
olsalazine, 603, 941
omeprazole, 111, 119, 165, 263, 269, 279, 285, 295, 303, 359, 367, 543, 549, 573, 619, 633, 639, 757, 829, 1001, 1015, 1029
Omori, M. *see* Yuno, K.
opiate agents, 919
oral–caecal transit time, 765
Osnes, M. *see* Aabakken, L.
Öst, Å. *see* Arlander, E.
osteoporosis, 777

Pakodi, F. *see* Hunyady, B.
pancreatic enzyme supplements, 771
pancreatic insufficiency, 771
pancreatic secretion, 967
pancreatin, 433
pancreatin—pharmacokinetics, 427
pancreatitis—pharmacology, 427
Pantaleone, U. *see* Spadaccini, A.
pantoprazole, 359, 397
Papa, A. *see* Cammarota, G.
Papa, A. *see* Tursi, A.
Parente, F., Maconi, G., Bargiggia, S., Colombo, E. & Bianchi

© 1996 Blackwell Science Ltd

Porro, G., Comparison of two lansoprazole–antibiotic combinations (amoxycillin or classical triple therapy) for treatment of *H. pylori* infection in duodenal ulcer patients, 211
Patchett, S.E. *see* Mulcahy, H.E.
patient tolerance, 975
pattern recognition, 353
Pazzi, P. *see* Dalla Libera, M.
Peitz, U. *see* Labenz, J.
Peled, Y. *see* Moshkowitz, M.
Penston, J.G. & Mistry, K.R., Eradication of *Helicobacter pylori* in general practice, 139
Penston, J.G. & Pounder, R.E., A survey of dyspepsia in Great Britain, 83
Penston, J.G., Review article: clinical aspects of *Helicobacter pylori* eradication therapy in peptic ulcer disease, 469
pentagastrin, 743
pepsin output, 497
pepsin secretion, 507
pepsinogen, 1021
peptic ulcer disease, 165, 347
peptic ulcer, 119, 619, 469, 647, 821, 1021
peroxidase, 333
Peterson, W.L. *see* Pounder, R.E.
Peterson, W.L., Ciociola, A.A., Sykes, D.L., McSorley, D.J., Webb, D.D. & The RBC *H. pylori* Study Group, Ranitidine bismuth citrate plus clarithromycin is effective for healing duodenal ulcers, eradicating *H. pylori* and reducing ulcer recurrence, 251
Peterson, W.L., Letter to the Editors, 1035
Petrillo, M. *see* Ardizzone, S.
Pfeltzer, C. *see* Wehrmann, T.
pH, 105
pharmacodynamics, 897
pharmacokinetics, 73, 897, 913
pharmacovigilance, 949
pH-metry, 295, 359
picotamide, 315
Pilotto, A., Di Mario, F., Franceschi, M., Leandro, G., Soffiati, G., Scagnelli, M., Bozzola, L. & Valerio, G., Cure of *Helicobacter pylori* infection in the elderly: effects of eradication on gastritis and serological markers, 1021
Pizzicannella, G. *see* Spadaccini, A.
Playford, R.J. & Macdonald, C.E., Letter to the Editors, 1035
Pommerien, W., Braun, M., Idström, J.-P., Wrangstadh, M. & Londong, W., Pharmacokinetic and pharmacodynamic interactions between omeprazole and amoxycillin in *Helicobacter pylori*-positive healthy subjects, 295
Pommerien, W., Schultze, V., Braden, B., Lembcke, B., Wrangstadh, M. & Londong, W., Dose–response of omeprazole combined with amoxycillin on duodenal ulcer healing and eradication of *Helicobacter pylori*, 303
porphyrin, 333
Porreca, E. *see* Neri, M.
portal circulation, 795
portal hypertension, 219
positron emission tomography, 681
pouchitis, 449
Pounder, R.E. & Peterson, W.L., Letter from the Editors, 217
Pounder, R.E. *see* Fraser, A.G.
Pounder, R.E. *see* Penston, J.G.
Pounder, R.E. *see* Wyeth, J.W.
precore, 199
prednisolone, 487
prednisone, 487
preparation for colonoscopy, 815
prescribing, 889
prescription survey, 661
primary biliary cirrhosis, 851
primary care, 233, 589
proctitis, 957
proctocolectomy, 449
proctocolitis, 39
propranolol, 795
prostaglandin, 111
protection, 859
proton pump inhibitors, 111, 289, 359, 865
Pryce, D.I. *see* Harris, A.W.
psoriasis, 851
pulse rate, 981

quadruple therapy, 647
quality of life, 91

Rabian, C. *see* Canva-Delcambre, V.
Raju, G.S., Bardhan, K.D., Royston, C. & Beresford, J., The management of refractory gastric ulcer using H_2-receptor antagonists, 387
Rambaud, J.-C. *see* Lémann, M.
Rampton, D.S. *see* Collins, C.E.
randomized controlled trial, 729
Ranganath, L. *see* Weldon, M.J.
ranitidine bismuth citrate, 241, 251, 625, 905
ranitidine, 119, 241, 347, 373, 529, 743, 749, 829, 913
Ratschek, M. *see* Stupnicki, Th.
Rauws, E.A.J. *see* Van der Hulst, R.W.M.
Rauws, E.A.J. *see* Wyeth, J.W.
Ravelli, G.-P. *see* Simon, B.
reactive oxygen metabolites, 737
rectal administration, 73
recurrence prevention, 821
Redhead, D.N. *see* Forrest, E.H.
Rees, W.D.W. *see* Lipscomb, G.R.
reflexologic technique, 919
reflux disease, 549
reflux oesophagitis, 397, 529, 549, 757
refractory Crohn's disease, 721
refractory gastric ulcer, 387
refractory, 39, 381
Reilly, T.G., Singh, S., Cottrell, J., Mann, S.G., Stauffer, L. & Walt, R.P., Low-dose famotidine and ranitidine as single post-prandial doses: a three-period placebo-controlled comparative trial, 749
reinfection, 193
relative risk, 251
renal dysfunction, 219

© 1996 Blackwell Science Ltd

repeat prescribing, 147
retreatment, 165
review, 843
Revillard, J.-P. *see* Canva-Delcambre, V.
Reynolds, P.D., Rhenius, S.T. & Hunter, J.O., Xanthine oxidase activity is not increased in the colonic mucosa of ulcerative colitis, 737
Rhenius, S.T. *see* Reynolds, P.D.
rheumatoid arthritis, 347, 851
Rhodes, J.M. *see* Stretch, G.L.
Richardson, P.D.I. *see* Bate, C.M.
Richardson, P.D.I. *see* Bell, G.D.
Riches, A. *see* Mulcahy, H.E.
RIII inhibition, 919
Rindi, G. *see* Annibale, B.
Rioux, K.P. & Wallace, J.L., Mast cells do not contribute to nonsteroidal anti-inflammatory drug-induced gastric mucosal injury in rodents, 173
risk factors, 589
Rizzello, F. *see* Gionchetti, P.
Robinet, E. *see* Canva-Delcambre, V.
ropivacaine, 73
Rowley, J.L. *see* Mee, A.S.
roxatidine, 187
Royston, C. *see* Raju, G.S.

safety, 949
salicylazosulphapyridine, 157
Salomon, R. *see* Szilagyi, A.
Sangaletti, O. *see* Lazzaroni, M.
Santo, M. *see* Moshkowitz, M.
Saraga, E. *see* Dorta, G.
Satzinger, U. *see* Stacher, G.
Savarino, V., Mela, G.S & Vigneri, S., Letter to the Editors, 447
Savarino, V., Mela, G.S., Zentilin, P., Mele, M.R., Vigneri, S., Mansi, C. & Celle, G., The effects of omeprazole 20 and 40 mg twice daily on intragastric acidity in duodenal ulcer patients, 367
Sawyerr, A.M. *see* Fraser, A.G.
Scagliarini, R. *see* Dalla Libera, M.
Scagnelli, M. *see* Pilotto, A.
Scarpignato, C., Kisfalvi, I., D'Amato, M. & Varga, G., Effect of dexloxiglumide and spiroglumide, two new CCK-receptor antagonists, on gastric emptying and secretion in the rat: evaluation of their receptor selectivity *in vivo*, 411
Schaufelberger, H.D. *see* Wyeth, J.W.
Schenk, B.E., Festen, H.P.M., Kuipers, E.J., Klinkenberg-Knol, E.C. & Meuwissen, S.G.M., Effect of short- and long-term treatment with omeprazole on the absorption and serum levels of cobalamin, 541
Schneider, C. *see* Stacher, G.
Schultze, V. *see* Pommerien, W.
Sciampa, G. *see* Spadaccini, A.
Seeger, L.L. *see* Bernstein, C.N.
Seery, J.P. *see* Jalan, R.
Seet, B.L. *see* How, W.
Segal, I. *see* Van Rensburg, C.J.
Seidman, E. *see* Szilagyi, A.
Selway, S. *see* McColm, A.A.
sensory pathways, 919
serum gastrin, 497, 507
Settle, C.D. & Wilcox, M.H., Review article: antibiotic-induced *Clostridium difficile* infection, 835
Severens, J.L. *see* Laheij, R.J.F.
Shanahan, F. *see* Bernstein, C.N.
Shaw, S. *see* Hirschowitz, B.I.
Sheen, I.-S. *see* Lin, D.-Y.
short chain fatty acids, 729
Sierrasesúmaga, L. *see* Azcona, C.
Silver, M.T., Murdock, R.H., Jr, Morrill, B.B. & Sue, S.O., Ranitidine 300 mg twice daily and 150 mg four-times daily are effective in healing erosive oesophagitis, 373
Simjee, A.E. *see* Van Rensburg, C.J.
Simon, B., Ravelli, G.-P., Goffin, H., Sucralfate gel versus placebo in patients with non-erosive gastro-oesophageal reflux disease, 441
Sindram, J.W. *see* Van Bodegraven, A.A.
Singh, S. *see* Reilly, T.G.
single post-prandial evening dose, 749
single proton emission computerised tomography, 123
Smith, M.S.H. *see* Fraser, A.G.
Smith, R. *see* Guan, R.
smoking, 165
Soffiati, G. *see* Pilotto, A.
Sogni, P. *see* Landry, C.
Solcia, E. *see* Annibale, B.
Soto, N. *see* Watanabe, S.
Spadaccini, A., De Fanis, D., Sciampa, G., Masciulli, V., Pantaleone, U., Di Virgilio, M., Magnarini, C. & Pizzicannella, G., Omeprazole versus ranitidine: short-term triple-therapy in patients with *Helicobacter pylori*-positive duodenal ulcer, 829
Spath, P. *see* Stupnicki, Th.
sphincter of Oddi motility, 421
Spies, S.K. *see* Van Rensburg, C.J.
Spiller, R. *see* Goddard, A.
Spiller, R.C. *see* Atherton, J.C.
Spiller, R.C. *see* Goddard, A.F.
spiroglumide, 411
Sridhar, S., Huang, J., O'Brien, B.J. & Hunt, R., Clinical economics review: cost-effectiveness of treatment alternatives for gastro-oesophageal reflux disease, 865
Stacher, G., Schneider, C., Steinringer, H., Satzinger, U. & Weber, U., Sublingual nitroglycerine: effects on contractile activity of the distal oesophagus and lower oesophageal sphincter in healthy men, 883
Ståhlbert, D. *see* Arlander, E.
Staiano, A. & Clouse, R.E., The effects of cisapride on the topography of oesophageal peristalsis, 875
Stanley, A.J. *see* Forrest, E.H.
Stauffer, L. *see* Grimley, C.E.
Stauffer, L. *see* Reilly, T.G.
Stein, C. *see* Laine, L.
Steinhart, A.H., Hiruki, T., Brzezinski, A., & Baker, J.P., Treatment of left-sided ulcerative colitis with butyrate enemas: a controlled trial, 729
Steinringer, H. *see* Stacher, G.

© 1996 Blackwell Science Ltd

steroids, 199, 487
Stevenson, A. *see* Stretch, G.L.
Stewart, C.A. *see* Termanini, B.
Stolte, M. *see* Labenz, J.
stomach, 173
Stretch, G.L., Campbell, B.J., Dwarakanath, A.D., Yaqoob, M., Stevenson, A., Morris, A.I., Rhodes, J.M., 5-amino salicylic acid absorption and metabolism in ulcerative colitis patients receving maintenance sulphasalazine, olsalazine or mesalazine, 941
Stupnicki, Th., Taufer, M., Denk, H., Ratschek, M., Spath, P. & Graf, K., Triple therapy with sucralfate, amoxycillin and metronidazole for healing duodenal ulcer and eradicating *Helicobacter pylori* infection, 193
subcutaneous, 807
sucralfate, 193, 441, 957
sucrose polyester, 715
Sue, S.O. *see* Silver, M.T.
Sugiyama, S. *see* Hisanaga, Y.
Sugiyama, S. *see* Tachi, K.
Sugiyama, T. *see* Kato, M.
Sukegawa, M. *see* Kato, M.
sulfasalazine, 1, 157, 661, 941
Susi, D. *see* Neri, M.
Swarbrick, E.T. *see* Hartley, M.G.
Sykes, D.L. *see* Peterson, W.L.
symptom improvement, 843
symptom relief, 757
systemic absorption, 603
systemic haemodynamics, 219
Szilagyi, A., Salomon, R. & Seidman, E., Influence of loperamide on lactose handling and oral–caecal transit time, 765

Tachi, K. *see* Hisanaga, Y.
Tachi, K., Goto, H., Hayakawa, T. & Sugiyama, S., Prevention of water immersion stress-induced gastric lesions through the enhancement of nitric oxide synthase activity in rats, 97
Takeda, H. *see* Kato, M.
Tan, M.F. *see* How, W.
Tang, H. & Neuberger, J., Review article: methotrexate in gastroenterology—dangerous villain or simply misunderstood?, 851
Tatsuta, M. *see* Yuno, K.
Taufer, M. *see* Stupnicki, Th.
Taylor, M.D. *see* Bate, C.M.
Taylor, M.D. *see* Bell, G.D.
Taylor-Robinson, S.D. *see* Jalan, R.
T-cell, 671
Tebano, M.T., Traversa, G., Da Cas, R. & Loizzo, A., Prescriptions for mesalazine and sulphasalzine: a prevalence estimate of patients treated for inflammatory bowel disease in Rome, 659
Ten Kate, F.J.W. *see* Van der Hulst, R.W.M.
Ten Wolde, S., Dijkmans, B.A.C., Janssen, M., Hermans, J., Lamers, C.B.H.W., High-dose ranitidine for the prevention of recurrent peptic ulcer disease in rheumatoid arthritis patients taking NSAIDs, 347
Termanini, B., Gibril, F., Stewart, C.A., Weber, H.C. & Jensen, R.T., A prospective study of the effectiveness of low dose omeprazole as initial therapy in Zollinger–Ellison syndrome, 61
tetracycline, 275
Tham, T.C.K. *see* Watson, R.G.P.
The Austro-Cis Study Group *see* Brunner, H.
The East-Danish Gallstone Study Group, Bile acid therapy versus placebo before and after extracorporeal shock wave lithotripsy of gallbladder stones, 651
The Lansoprazole Clinical Research Group *see* Mee, A.S.
The RBC *H. pylori* Study Group *see* Peterson, W.L.
Theiß, U. *see* Hartmann, M.
Theron, I. *see* Van Rensburg, C.J.
Thiesen, A. & Thomson, A.B.R., Review article: older systemic and newer topical glucocorticosteroids and the gastrointestinal tract, 487
Thompson, R.P.H. *see* Jenkins, A.P.
Thomson, A.B.R. *see* Thiesen, A.
thromboxane, 315
Tildesley, G. *see* Bell, G.D.
Tillenburg, B. *see* Labenz, J.
Tillman, L.A., Drake, F.M., Dixon, J.S. & Wood, J.R., Review article: safety of bismuth in the treatment of gastrointestinal diseases, 459
tinidazole, 285, 1015
Tiomny, E. *see* Moshkowitz, M.
TIPSS, 795, 801
tolerability, 397
topical pharyngeal anaesthesia, 975
Traversa, G. *see* Tebano, M.T.
treatment outcome, 387
treatment, 157, 433, 771, 1005, 1029
Trevethick, M.A. *see* Clayton, N.M.
triple therapy, 49, 207, 275, 997, 1009, 1015
tripotassium dicitrato bismuthate, 279
Trua, F. *see* Tursi, A.
Trujillo, M. *see* Laine, L.
Tursi, A. *see* Cammarota, G.
Tursi, A., Cammarota, G., Montalto, M., Papa, A., Veneto, G., Cuoco, L., Trua, F., Branca, G., Fedeli, G. & Gasbarrini, G., Low-dose omeprazole plus clarithromycin and either tinidazole or amoxycillin for *Helicobacter pylori* infection, 285
Tuynman, H.A.R.E. *see* Van Bodegraven, A.A.
Tytgat, G.N.J. *see* Van der Hulst, R.W.M.

ulcer complications, 507
ulcer healing drugs, 147
ulcer recurrence, 193
ulcerative colitis, 39, 73, 123, 157, 315, 321, 327, 729, 737, 777, 941
ulcers, 173, 859, 985
unsedated upper gastrointestinal endoscopy, 975
urea breath test, 981

Valerio, G. *see* Pilotto, A.
Van Bodegraven, A.A., Boer, R.O., Lourens, J., Tuynman, H.A.R.E. & Sindram, J.W., Distribution of mesalazine enemas in active and quiescent ulcerative colitis, 327

© 1996 Blackwell Science Ltd

Van de Lisdonk, E.H. *see* Laheij, R.J.F.
Van der Ende, A. *see* Van der Hulst, R.W.M.
Van der Hulst, R.W.M., Weel, J.F.L., Verheul, S.B., Keller, J.J., Ten Kate, F.J.W., Van der Ende, A., Rauws, E.A.J., Dankert, J. & Tytgat, G.N.J., Treatment of *Helicobacter pylori* infection with low or high dose omeprazole combined with amoxycillin and the effect of early retreatment, 165
Van Rensburg, C.J., Honiball, P.J., Grundling, H. de K., Van Zyl, J.H., Spies, S.K., Eloff, F.P., Simjee, A.E., Segal, I., Botha, J.F., Cariem, A.K., Marks, I.N., Theron, I. & Bethke, T.D., Efficacy and tolerability of pantoprazole 40 mg versus 80 mg in patients with reflux oesophagitis, 397
Van Rensburg, C.J., Louw, J.A., Girdwood, A.H., Simjee, A.E. & Marks, I.N., A trial of lansoprazole in refractory gastric ulcer, 381
Van Zyl, J.H. *see* Van Rensburg, C.J.
Varga, G. *see* Scarpignato, C.
Veneto, G. *see* Cammarota, G.
Veneto, G. *see* Tursi, A.
Venturi, A. *see* Gionchetti, P.
Verbeek, A.L.M. *see* Laheij, R.J.F.
Verheul, S.B. *see* Van der Hulst, R.W.M.
Vidon, N. *see* Landry, C.
Vigneri, S. *see* Savarino, V.
visceral desensitizing drug, 919
Vouillamoz, D. *see* Dorta, G.

Walker, M.M. *see* Harris, A.W.
Wallace, J.L. *see* Rioux, K.P.
Walsh, J.H. *see* Ciociola, A.A.
Walt, R.P. *see* Reilly, T.G.
Walters, M.P. & Littlewood, J.M., Pancreatin preparations used in the treatment of cystic fibrosis—lipase content and *in vitro* release, 433
Wang, X.-E. *see* Watanabe, S.
Watanabe, S., Wang, X.-E., Hirose, M., Yoshizawa, T., Iwazaki, R., Oide, H., Kitamura, T., Miwa, H., Miyazaki, A. & Soto, N., Effects of rebamipide on bile acid-induced inhibition of gastric epithelial repair in a rabbit cell culture model, 927
water immersion stress, 97, 933
Watson, R.G.P., Johnston, B.T., Tham, T.C.K. & Kersey, K., Effervescent and standard formulations of ranitidine—a comparison of their pharmacokinetics and pharmacology, 913
Watts, D.A. *see* Bate, C.M.
Webb, D.D. *see* Ciociola, A.A.
Webb, D.D. *see* Peterson, W.L.
Weber, H.C. *see* Termanini, B.
Weber, U. *see* Stacher, G.
Wee, A. *see* Guan, R.
Weel, J.F.L. *see* Van der Hulst, R.W.M.
Wehrmann, T., Pfeltzer, C. & Caspary, W.F., Effect of erythromycin on human biliary motility, 421
weight loss, 579
Weldon, M.J., Broadbent, A., Chambers, S., Mistry, R., Ranganath, L. & Gould, S.R. A seven-day *Helicobacter pylori* treatment regimen using clarithromycin, omeprazole and tripotassium dicitrato bismuthate, 279
Weldon, M.J., Lowe, C., Joseph, A.E.A. & Maxwell, J.D., Review article: quantitative leucocyte scanning in the assessment of inflammatory bowel disease activity and its response to therapy, 123
West, J.M. *see* Grimley, C.E.
Whorwell, P.J. *see* Houghton, L.A.
Whorwell, P.J. *see* Maxton, D.G.
Wijdenes, J. *see* Canva-Delcambre, V.
Wilcox, M.H. *see* Settle, C.D.
Willer, J.-C. *see* Coffin, B.
Williams, D.R.R. *see* Bodger, K.
Williams, L.V. *see* Clayton, N.M.
Williamson, R. *see* McColm, A.A.
Windsor, A.J. *see* Guillou, P.J.
Wood, J.R. *see* Dixon, J.S.
Wood, J.R. *see* Tillman, L.A.
Woods, K.L., Keife, C. & Graham, D.Y., How accurate is the determination of blood in gastric juice? Comparison of peroxidase and porphyrin methods, 333
Worning, H. *see* Nørregaard, P.
Wrangstadh, M. *see* Pommerien, W.
Wurst, W. *see* Hartmann, M.
Wyeth, J.W., Pounder, R.E., Duggan, A.E., O'Morain, C.A., Schaufelberger, H.D., De Koster, E.H., Rauws, E.A.J., Bardhan, K.D., Gilvarry, J., Buckley, M.J.M., Gummett, P.A. & Logan, R.P.H., The safety and efficacy of ranitidine bismuth citrate in combination with antibiotics for the eradication of *Helicobacter pylori*, 623

xanthine oxidase, 737

Yap, I. *see* Guan, R.
Yaqoob, M. *see* Stretch, G.L.
Yeoh, K.G. *see* Guan, R.
Yoshimura, K., Delbarre, S.G., Kraus, E. & Boland, C.R., The effects of omeprazole and famotidine on mucin and PGE_2 release in the rat stomach, 111
Yoshizawa, T. *see* Watanabe, S.
Young, G. *see* Lewis, S.J.
Yousfi, M.M., El-Zimaity, H.M.T., Genta, R.M. & Graham, D.Y., One-week triple therapy with omeprazole, amoxycillin and clarithromycin for treatment of *Helicobacter pylori* infection, 617
Yousfi, M.M., El-Zimaty, H.M.T., Cole, R.A., Gental, R.M. & Graham, D.Y., Metronidazole, ranitidine and clarithromycin combination for treatment of *Helicobacter pylori* infection (modified Bazzoli's triple therapy), 119
Yuno, K., Iishi, H., Tatsuta, M., Hifumi, K. & Omori, M., Intravenous midazolam as as sedative for colonoscopy: a randomized, double-blind clinical trial, 981

Zentilin, P. *see* Savarino, V.
Zinsmeister, A.R. *see* Camilleri, M.
Zollinger–Ellison syndrome relapse, 507

© 1996 Blackwell Science Ltd